DPP4 and COVID-19: While, given its glucose-dependent effects and the risk of hypoglycemia thought to be relatively low with this DPP-4 inhibitor, the use of DPP-4 inhibitors as a class may be deemed relatively safe in these patients mild to moderate COVID-19, consideration should be given to switching to insulin in patients with severe COVID-19.